Agios Pharma (AGIO) Reports Updated Data for Mitapivat from Extension Phase of DRIVE PK Study in Patients with Pyruvate Kinase Deficiency
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Pre-Open Movers 12/09: (THOR) (XBIT) (ARQL) Higher (DPLO) (THO) (M) Lower (more...)
December 9, 2019 9:29 AM ESTPre-Open Movers
Synthorx, Inc. (NASDAQ: THOR) 169.3% HIGHER; Sanofi (NYSE: SNY) and Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company focused on prolonging and improving the lives of people suffering from cancer and autoimmune disorders, entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Synthorx for $68 per share in cash, which represents an aggregate equity value of approximately $2.5 billion (on a fully diluted basis).
XBiotech Inc. (NASDAQ:... More
Agios Pharma (AGIO) Presents Translational Data to Further Characterize the Role of TIBSOVO Treatment in IDH1 Mutant AML
December 9, 2019 8:06 AM ESTAgios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today presented translational data describing deep and durable molecular responses to treatment of TIBSOVO® (ivosidenib) and azacitidine and mechanisms of resistance and relapse to single agent treatment with TIBSOVO® in acute myeloid leukemia (AML) with an IDH1 mutation. The data were presented as part of the scientific program at the 2019 American Society of Hematology (ASH) Annual Meeting.
For 10 years, we have pioneered the science behind the role of IDH mutations in AML,... More
Agios Pharma (AGIO) Confirms Proof-of-Concept for Mitapivat (AG-348) Based on Preliminary Phase 2 Results in Patients with Non-Transfusion-Dependent Thalassemia
December 9, 2019 6:30 AM ESTAgios Pharmaceuticals, Inc. (NASDAQ: AGIO) today announced that clinical proof-of-concept has been established based on a preliminary analysis of the Phase 2 trial of mitapivat (AG-348) in patients with non-transfusion-dependent thalassemia. Mitapivat is an investigational, first-in-class, oral, small molecule allosteric activator of wild-type and a variety of mutated pyruvate kinase-R (PKR) enzymes.
The Phase 2 study has enrolled 12 of the intended 17 patients (nine with -thalassemia and three with -thalassemia). As of the November 14, 2019 data cutoff date, eight patients, all with -thalassemia, were evaluable for the primary endpoint of a hemoglobin increase of 1.0 g/dL... More
